brain-cancer

New lab model tracks how glioblastoma evolves resistance to chemo and radiation separately, revealing distinct escape routes

Glioblastoma almost always comes back after treatment, and recurrent GBM is almost always fatal. A major obstacle to understanding why has been the lack of matched models — lab systems that let you compare the same tumor before and after it became resistant.

Researchers addressed this by developing 'resistant GSC families': stem-like cell lines derived from the same patient tumor, but separately selected for resistance to chemotherapy (temozolomide/TMZ) or radiation — alongside an untreated control. This design lets you dissect what specifically each treatment pressure does to the tumor, rather than looking at a jumbled picture of recurrence.

Key findings include: TMZ resistance either comes from mismatch repair gene loss (stable genetic resistance) or a non-genetic drug tolerance independent of MGMT status. Radiation resistance involves adaptive DNA damage response and cell-cycle changes. Both paths lead to chromosomal instability and increased receptor tyrosine kinase activity — potential new vulnerabilities.

Key Findings

Resistant GSC family platform enables pressure-specific dissection of chemo vs radiotherapy resistance evolution from the same primary tumor
TMZ resistance arises via two distinct routes: MMR-dependent stable resistance or MGMT-independent drug tolerance
Radiation resistance involves adaptive DNA damage response and cell-cycle reprogramming
Both treatment pressures drive chromosomal alterations and increased receptor tyrosine kinase activity
Platform enables hypothesis-driven testing of strategies to prevent or overcome GBM recurrence

Implications

This platform fills a real gap in GBM research. By separating chemotherapy and radiation resistance into distinct tractable models, it enables mechanistic studies that were previously impossible. The finding of MGMT-independent TMZ tolerance is particularly significant — MGMT status is currently the main biomarker used to guide TMZ decisions, and this challenges its completeness. Increased RTK activity in resistant cells suggests actionable therapeutic vulnerabilities.

Caveats

Preprint — not peer reviewed. Ex vivo models may not fully recapitulate the tumor microenvironment and immune context of in vivo resistance. Patient sample numbers not specified. Results need prospective validation. The platform is a research tool, not a clinical test.

Source: bioRxiv — 2026-04-06

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.